Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. [electronic resource]
Producer: 20171226Description: 2059-2066 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Breast Neoplasms -- drug therapy
- Class I Phosphatidylinositol 3-Kinases -- antagonists & inhibitors
- Disease-Free Survival
- Female
- Humans
- Indazoles -- administration & dosage
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local -- drug therapy
- Paclitaxel -- administration & dosage
- Receptor, ErbB-2 -- genetics
- Sulfonamides -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.